Efficacy of Lu 31-130 in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• The subject has a primary diagnosis of schizophrenia

• The subject experiences clinically significant symptoms

• The subject is willing to be hospitalized during the initial period of the study

• The subject has normal serum values of parameters associated with liver function